

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | |
|---|---------------------------|
| In re application of | Docket No: Q57234 |
| Yoshihisa NISHIBE, et al. | Allowed: January 26, 2005 |
| Appln. No.: 09/446,276 | Group Art Unit: 1615 |
| Confirmation No.: 2101 | Examiner: Amy E. Pulliam |
| Filed: December 21, 1999 | Issued: September 6, 2005 |
| U.S. Patent No.: 6,939,559 | |
| For: PHARMACEUTICAL COMPOSITION FOR APPLICATION TO MUCOSA | |

SUBMISSION OF ART

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

For the possible benefit of anyone subsequently evaluating the scope and/or validity of the above-identified patent, it is requested that the document that is listed below (copy enclosed) be placed in the U.S. Patent and Trademark Office's file wrapper of the above-identified U.S. patent:

Abstract- "Non-oral administration of progesterone: experiences and possibilities of the transvaginal route", Schweiz Rundsch Med Prax, 1995 Feb. 1, 84(5): 127-33.


The undersigned has not reviewed the teachings of the above-listed document in detail and thus makes no representations concerning the relevancy or materiality of the above-listed document.

SUBMISSION OF ART
U.S. Application No.: 09/446,276

Attorney Docket No.: Q57234

This is not an Information Disclosure Statement and no response from the U.S. Patent
and Trademark Office is believed to be necessary, nor are any fees believed to be due.

Respectfully submitted,


Jennifer M. Hayes
Registration No. 40,641


SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: September 11, 2007



PubMed Nucleotide Protein Genome Structure PopSot Taxonomy OMIM

Search PubMed for [] Limits Preview/Index History Clipboard

About Entrez

Entrez PubMed

Overview

Help | FAQ

New/Noteworthy

PubMed Services

Journal Browser

MeSH Browser

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

Cubby

Related Resources

Order Documents

Grateful Med

Consumer Health

Clinical Alerts

ClinicalTrials.gov

Privacy Policy

1: Schweiz Rundsch Med Prax 1995 Feb 1;84
(5):127-33

Related Articles, Books,
LinkOut

[Non-oral administration of progesterone: experiences and possibilities of the transvaginal route].

[Article in French]

de Ziegler D, Seidler L, Scharer E, Bouchard P

Service d'endocrinologie gynécologique, Clinique de Genolier.

Recent development of transdermal therapy permits application of estrogen, usually produced in the ovaries, in physiological dosage by means of continuous release from either an epidermal patch or dermal application of a gel. Transdermal therapy with progesterone, however is impossible due to poor dermal absorption and high dose requirements (release from corpora lutea: 25 mg/24 hours). Two other possibilities have been proposed. On one hand it is possible to apply norethisterone-acetate (NETA), another gestagen, epicutaneously. This mode of administration carries the same problems as oral application thus allowing for a dose reduction. On the other hand progesterone can be applied vaginally. This mode leads to significantly higher plasmatic concentrations of progesterone and has effects on the uterine mucosa similar to those in a normal cycle. This modality thus permits application of estradiol and progesterone in a physiological manner by a non oral route. It appears particularly interesting in patients at cardiovascular risk.

Publication Types:

- Review
- Review, tutorial

PMID: 7878312, UI: 95183849



[Write to the Help Desk](#)